Danish GOAL trial to test semaglutide in adolescents on antipsychotics

The wire

1. 01Participants on stable antipsychotic treatment will receive once-weekly subcutaneous semaglutide up to 2.4 mg for 36 weeks alongside standard care, followed by 18 months of observational follow-up.
2. 02Targets a group with antipsychotic-associated obesity and limited evidence-based options; secondary outcomes include BMI SD score, body composition, metabolic biomarkers and psychiatric outcomes.
3. 03The primary outcome is study completion rate, not weight loss; the design is single-arm and uncontrolled and is intended only to inform a later randomised trial.

From the source

Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study

BMJ open · 2026 Sep 17 · Giraldi LV, Andersen JT, Jespersen J et al.